SpyGlass Pharma is pursuing a $100 million IPO to advance its glaucoma drug delivery platform through Phase 3 trials. Read ...
ALEXANDRIA, MN - January 24, 2026 - PRESSADVANTAGE - Individuals living with or at risk for glaucoma in the region can ...
The authors noted that this is the first prospective case series to apply a structured, protocol-based approach to ...
Clinicians seem to generally use intraocular pressure (IOP) as a continuous risk factor in their treatment patterns in ...
A study published in Cureus showed that omidenepag isopropyl achieved significant and sustained reductions in intraocular ...
SpyGlass Pharma has randomized the first patients in its 2 registrational phase 3 clinical trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System) for the lowering of intraocular pressure (IOP) ...
Eye pressure, medically called Intraocular Pressure (IOP), refers to the pressure created by the fluid inside your eye.
Hemodialysis significantly alters anterior and posterior eye segments, affecting parameters like anterior chamber depth, lens ...
SpyGlass Pharma, a late-stage biopharmaceutical company, today announced that the first patients have been randomized in two registrational Phase III clinical trials of its lead product candidate, the ...
The study found significant intra-group CMT reductions in the DEX-I group, with a higher percentage reduction than the ...
Researchers have predicted that cases of glaucoma, a common eye condition that can lead to blindness if not treated, are ...
Researchers have identified a metabolically sensitive cell subtype in the eye's drainage system which shows early signs of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback